References
  1. Rowin EJ, Link MS, Maron MM, Maron BJ. Evolving contemporary management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 2023;148:1797–1811.
  2. Masri A, Kanj M, Thamilarasan M, Wazni O, Smedira NG, Lever HM, Desai MY. Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: A survival meta-analysis. Cardiovasc Diagn Ther 2017;7:36–44.
  3. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff H V., Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 2020;76:e159–e240.
  4. Rowin EJ, Wadid M, Maron MS, White M, Hook B, Harnish P, Silver J, Reynolds M, Maron B. Assessing the impact of atrial fibrillation on symptoms and quality of life in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2024 (final reference to be provided by editor on publication).
  5. Spertus JA, Jones PG, Sandhu AT, Arnold S V. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;76:2379–2390.
  6. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:15–25.
  7. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149: e1-e156.
  8. Desai MY, Tower-Rader A, Szpakowski N, Mentias A, Popovic ZB, Smedira NG. Association of Septal Myectomy with Quality of Life in Patients with Left Ventricular Outflow Tract Obstruction from Hypertrophic Cardiomyopathy. JAMA Netw Open 2022;5(4):e227293. doi:10.1001/jamanetworkopen.2022.7293
  9. Holmes DN, Piccini JP, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, O’Brien EC, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson ED, Thomas L, on behalf of the ORBIT AF Investigators and Patients. Defining Clinically Important Difference in the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Score: Results from the ORBIT-AF Registry. Circ Cardiovasc Clin Outcomes 2019;12:e005358. DOI: 10.1161/CIRCOUTCOMES.118.005358
  10. Mark DB, Anstrom K, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL, for the CABANA Investigators. Effect of Catheter Ablation vs. Medical Therapy on Quality of Life Among Patients with Atrial Fibrillation. The Cabana Randomized Clinical Trial. JAMA 2019;321(13):1275-1285.
  11. Castagno D, Donna P Di, Olivotto I, Frontera A, Calò L, Scaglione M, Arretini A, Anselmino M, Giustetto C, Ferrari GM De, Cecchi F, Haissaguerre M, Gaita F. Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes. J Cardiovasc Electrophysiol 2021;32:657–666.
  12. Capota R, Militaru S, Ionescu AA, Rosca M, Baicus C, Bogdan AP, Jurcut R: Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health Qual Life Outcomes 2020;18,351.doi.org/10.1186/s12955-020-01604-9
  13. Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, Li W, Dolan C, Reaney M, Sehnert AJ, Jacoby D. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021;397: 2467-2475.